Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab autoinjector bioequivalence study in healthy volunteers
NCT06475729Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mirikizumab (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration at 1704 hours, Area Under the Concentration Versus Time Curve From Time Zero to Infinity at 1704 hours and 1 more. Started Jun 2024; status: completed.
02
Drugs
mirikizumab
Beyond the preview
Go deeper on NCT06475729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475729.